王祺玥，校聘副教授。

2018年6月博士毕业于中国药科大学拼搏体育官方。2018年7月-2021年7月于美国内布拉斯加大学医学中心博士后研究员； 2021年11月加入拼搏体育官方(中国)有限公司。近年来在Biomaterials, Journal of Controlled Release, Advanced Healthcare Materials, Chinese Chemical Letters, Drug Delivery等国际权威药学期刊上共发表学术论文十余篇。授权发明专利一项。担任Advanced Drug Delivery Review, Int J Nanomed, Pharmaceutics, OpenNano等期刊审稿人。

研究方向：

1. 肺部给药平台开发及局部疾病治疗；

2. 脑靶向给药系统开发及髓母细胞瘤治疗；

3. 寡核苷酸和基于 miRNA 的疗法的递送和靶向；

4.新型药用辅料的开发与应用研究。

教育背景及工作经历：

2021.11至今      校聘副教授   药剂学                     拼搏体育官方

2018.7-2021.7     博士后           药剂学         内布拉斯加大学医学中心

2017.11-2018.4   访问学者       药剂学         内布拉斯加大学医学中心

2015.9-2018.6     博士               药剂学                     中国药科大学

2012.9-2015.6     专业硕士       药学                         中国药科大学

2008.9-2012.6     本科               药学                         中国药科大学

科研项目：

（1）2017年度江苏省研究生科研与实践创新计划项目，KYCX17_0674，富马酰基二酮哌嗪为载体的抗生素干粉吸入剂的研究，2017-2018，主持；

（2）NIH，1 R01 NS116037-01， Overcoming Resistance Mechanisms in Hedgehog & Myc-amplified Medulloblastoma，2020-2021年度，参与；

代表性科研成果：

1. Q Wang¹, J Liu¹, D Chen¹, S Miao, J Wen, C Liu, S Xue, Y Liu, Q Zhang, Y Shen^*. “Cluster Bomb” based Bismuth nano‐in‐micro spheres formed dry powder inhalation for thermo‐radio sensitization effects of lung metastatic breast cancer. Advanced Healthcare Materials, 2023, 2202622.

2. J Wen¹, C Liu¹, J Liu¹, L Wang, S Miao, D Chen^*, Q Wang^*, M Huo^*, Y Shen^*. Dextran 40 hybrid biomimetic bismuth-nanoflower designed for NIR II-triggered hypoxic tumor thermoradiotherapy via macrophage escape. Carbohydrate Polymers, 2023, 120697.

3. Q Wang^*, J Liu. Medulloblastoma: immune microenvironment and targeted nano-therapy. OpenNano, 2022, 100035.

4. Y Liu¹, Y Li¹, P Xu, Y Shen, B Tang^*, Q Wang^*. Development of abiraterone acetate nanocrystal tablets to enhance oral bioavailability: formulation optimization, characterization, in vitro dissolution and pharmacokinetic evaluation. Pharmaceutics, 2022, 14(6): 1134.

5. S Xue, J Jiao, S Miao, L Wang, Y Liu, Q Zhang, Q Wang, Y Xi^*, Y Zhang^*. Lipid‐coated bismuth nanoflower as the thermos‐radio sensitizer for therapy of lung metastatic breast cancer: Preparation, optimization, and characterization. IET Nanobiotechnology, 2022, 16(9): 305-315.

6. Q Wang¹, L Ge¹, L Wang, Y Xu, S Miao, G Yu^*, Y Shen^*. Formulation optimization and in vitro antibacterial ability investigation of azithromycin loaded FDKP microspheres dry powder inhalation. Chinese Chemical Letters, 2021, 32(3): 1071-1076.

7. V Kumar¹, Q Wang¹, B Sethi, F Lin, V Kumar, DW Coulter, Y Dong, RI Mahato^*. Overcoming resistance mechanisms in hedgehog and myc-amplified medulloblastoma. Biomaterials, 2021, 278, 121138.

8. Q Wang¹, Y Shen¹, G Mi, D He, Y Zhang, Y Xiong, TJ Webster^*, J Tu^*. Fumaryl diketopiperazine based effervescent microparticles to escape macrophage phagocytosis for enhanced treatment of pneumonia via pulmonary delivery. Biomaterials, 2020, 228, 119575.

9. Q Wang, V Kumar, F Lin, B Sethi, DW Coulter, TR McGuire, RI Mahato^*. ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice. Journal of Controlled Release, 2020, 323, 463-474.

10. X Xin¹, F Lin¹, Q Wang, L Yin^*, RI Mahato^*. ROS-Responsive polymeric micelles for triggered simultaneous delivery of PLK1 Inhibitor/miR-34a and effective synergistic therapy in pancreatic cancer. ACS applied materials & interfaces, 2019, 11 (16), 14647-14659.

11. Y Xia¹, Y Su¹, Q Wang, C Yang, B Tang, Y Zhang, J Tu^*, Y Shen^*. Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation. Drug Delivery, 2019, 26(1): 650-660.

12. Q Wang, G Mi, D Hickey, Y Li, J Tu^*, TJ Webster^*, Y Shen^*. Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia. Biomaterials, 2018, 160, 107-123.

13. Q Wang¹, C Sun¹, B Xu, J Tu^*, Y Shen^*. Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. Drug Delivery, 2018, 25,59-69.

14. M Li¹, Y Du¹, Q Wang, C Sun, X Ling, B Yu^*, J Tu^*, Y Xiong^*. Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation. Drug development and industrial pharmacy, 2016, 42(4): 676-684.

15. X Ling, C Zhao, L Huang, Q Wang, J Tu^*, Y Shen^*, C Sun^*. Synthesis and characterization of hyaluronic acid–platinum (iv) nanoconjugate with enhanced antitumor response and reduced adverse effects. RSC advances, 2015, 5(99): 81668-81681.

Book Chapters

1. X Xin, Q Wang, V Kumar, AS Narang, RI Mahato, 2022, Protein and peptide delivery to the lung via inhalation. Organ Specific Drug Delivery and Targeting to the Lungs (1st ed.), AS Narang, RI Mahato (Eds), Boca Raton, ‎FL: CRC Press.

PATENTS:

1. J Tu, Q Wang, C Sun, Y Shen, 2022, Inhalable effervescent DPI and its application in the preparation of infectious pneumonia medicine, China Petent: CN 111544420 B

E-mail: qiyuewang@njtech.edu.cn; lazioayanami@gmail.com;